Lupin Bags First US Rival To $1.6bn Ingrezza – But Launch Will Have To Wait
Firm Receives First And So Far Only FDA Approval For Valbenazine 40mg And 80mg Capsules
Lupin has claimed the first US approval for an Ingrezza generic – but must wait well over a decade before launching its version of valbenazine, after last year striking a patent litigation settlement with originator Neurocrine Biosciences.
